Asked by: Nigel Adams (Conservative - Selby and Ainsty)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what the per capita funding for the Vale of York Clinical Commissioning Group (CCG) is in 2015-16; and what the equivalent funding is for each of that CCG's 10 most similar CCG's.
Answered by Alistair Burt
The table below shows the NHS Vale of York Clinical Commissioning Group (CCG) funding per capita allocation for 2015-16.
CCG |
|
| Per capita allocation, 2015-16 £ |
NHS Vale of York CCG |
|
| 1,079 |
The table below shows the same information as above for the 10 most similar CCGs to NHS Vale of York CCG, determined using the NHS England Commissioning for Value online tool.
CCG |
|
| Per capita allocation, 2015-16 £ |
NHS West Leicestershire CCG |
|
| 1,041 |
NHS Lincolnshire West CCG |
|
| 1,145 |
NHS East Riding Of Yorkshire CCG |
|
| 1,177 |
NHS Bath And North East Somerset CCG |
|
| 1,062 |
NHS South Worcestershire CCG |
|
| 1,069 |
NHS Guildford And Waverley CCG |
|
| 1,033 |
NHS West Cheshire CCG |
|
| 1,213 |
NHS North East Essex CCG |
|
| 1,215 |
NHS South Warwickshire CCG |
|
| 1,090 |
NHS Canterbury And Coastal CCG |
|
| 1,120 |
Sources:
2015-16 CCG allocations are published on the NHS England website as Annex B to the Allocations publication letter 2015-16, available at:
https://www.england.nhs.uk/resources/resources-for-ccgs/#finance.
The 10 most similar CCGs are from Commissioning for Value resources available at:
https://www.england.nhs.uk/resources/resources-for-ccgs/comm-for-value/.
Note:
There are many reasons why allocations for similar CCGs differ. These include differences in demographics, deprivation, distance from target and the Market Forces Factor.
Asked by: Nigel Adams (Conservative - Selby and Ainsty)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, with reference to the recommendations of the Health Quality Improvement Partnership National Clinical Audit for Rheumatoid and Early Inflammatory Arthritis, what steps his Department is taking to encourage clinical commissioning groups to take a more proactive approach towards rheumatology commissioning.
Answered by Jane Ellison
The National Clinical Audit and Patient Outcomes Programme (NCAPOP) is managed on behalf of NHS England by the Healthcare Quality Improvement Partnership (HQIP). The first annual report of the National Clinical Audit of Rheumatoid and Early Inflammatory Arthritis was published on 22 January 2016. NCAPOP audits help drive improvement by providing local trusts with individual benchmarked reports on their performance against a range of measures, feeding back comparative findings to help participants identify necessary improvements for patients. The Rheumatoid and Early Inflammatory Arthritis audit has set recommendations for local NHS services including: improved support and training for primary care; increased clinical capacity in rheumatology services; and to improve the collection of outpatient data.
Following the first national Rheumatoid and Early Inflammatory Arthritis Audit, HQIP has reported that a number of trusts have successfully reconfigured their services in order to improve patient care. More information can be found at the following link:
www.hqip.org.uk/national-programmes/a-z-of-nca/arthritis-rheumatoid-and-early-inflammatory
Asked by: Nigel Adams (Conservative - Selby and Ainsty)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what discussions he has had with the Home Secretary on the frequency of use of police detention facilities for mental health patients who pose a risk to themselves or others when mental health facilities are full or unavailable.
Answered by Alistair Burt
Our departments have worked closely to achieve a reduction of 54% in the use of police custody as a place of safety in the last three years. We intend to amend primary legislation to further reduce its use and are investing up to £15 million in 2016-17 to help achieve this.
Asked by: Nigel Adams (Conservative - Selby and Ainsty)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what assessment he has made of progress in diagnosing and treating cervical cancers more effectively in the last five years; and if he will make a statement.
Answered by Jane Ellison
We recognise that cervical screening continues to play a key role in preventing women getting, and being harmed by, cervical cancer. The NHS Cervical Screening Programme in England offers screening to women aged 25 to 49 every three years, and women aged 50 to 64 every five years. Women aged over 65 should only be screened if they have not been screened since age 50 or if they have had recent abnormal results.
Human papillomavirus (HPV) testing as triage for women with mild and borderline results and as a test of cure for women previously treated for cervical abnormalities became routine across the NHS Cervical Screening Programme from 1 April 2014. This makes cervical screening more targeted and significantly reduces the need for repeat testing. It is estimated that over 160,000 women a year do not need repeat tests due to mild or borderline results and around 400,000 women have been removed from ten year annual follow-up due to a previous abnormal result.
In April 2012, the UK National Screening Committee (UK NSC), which advises Ministers and the National Health Service in all four countries about all aspects of screening policy and supports implementation, gave its support for a pilot to assess the value of using HPV testing as primary screening for cervical disease, rather than the currently used cytology test. The pilot has been establishing the feasibility of using HPV as the primary screen for cervical disease in order to achieve better outcomes for women, while minimising over-treatment and anxiety, and whether it is practical to roll out nationally. The UK NSC opened a public consultation on this in July 2015. The consultation closes on 2 November 2015. Ministers expect to receive a recommendation from the UK NSC following the closure of the public consultation.
Earlier diagnosis and prevention is a key focus of the Independent Cancer Taskforce report, Achieving World-Class Cancer Outcomes: A Strategy for England 2015-2020. It includes a recommendation that, assuming a positive recommendation by the NSC, Public Health England and NHS England should drive a rapid roll-out of primary HPV testing into the cervical screening programme. The Taskforce also made a number of recommendations on the early diagnosis of cancers more generally.
In addition, the National Institute for Health and Care Excellence has published a range of guidance on the treatment and screening of cervical cancer and further information is available at:
www.nice.org.uk/guidance/conditions-and-diseases/cancer/cervical-cancer